Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios. A Dana-Farber Cancer Institute study also indicated that telemedicine may considerably cut cancer treatment greenhouse gas emissions. Under these circumstances, telehealth stocks will only gain favor with the investing community. That's why we'll explore three undervalued telehealth stocks, each wit ...

Core Insights - Health Catalyst has successfully acquired Carevive Systems, enhancing its capabilities in oncology-focused health technology [1][2] - The acquisition aims to improve patient care and outcomes in oncology through better data and analytics [3][4] Company Overview - Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations, leveraging a cloud-based data platform with over 100 million patient records [5] - Carevive Systems specializes in oncology, focusing on improving the patient experience and providing data for treatment planning and clinical trials [2][4] Strategic Importance - The acquisition is seen as a pivotal moment for both companies, emphasizing the importance of high-quality data in oncology care [3][4] - The partnership aims to amplify the patient's voice in cancer care and enhance the delivery of innovative solutions to cancer centers [4]

Core Insights - Health Catalyst, Inc. is actively participating in upcoming investor conferences, indicating a focus on investor engagement and communication [1] - The company is a leading provider of data and analytics technology and services specifically tailored for healthcare organizations [2] Company Overview - Health Catalyst aims to drive significant, measurable improvements in healthcare through data-informed decision-making [2] - The company utilizes a cloud-based data platform that integrates data from over 100 million patient records, encompassing trillions of facts [2] - Health Catalyst's offerings include analytics software and professional services to help clients achieve clinical, financial, and operational enhancements [2] Upcoming Events - Jason Alger, CFO, and Jack Knight, VP of Investor Relations, will participate in the Stifel Cross Sector Insight Conference on June 4, 2024, at 9:45am ET [1] - The company will also present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 8:40am ET [1]

Investors might want to bet on Health Catalyst (HCAT) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. 12 Month EPS Current-Quarter Estimate Revisions The earnings estimate of $0.09 per share for the current quarter represents a change of +80% from the number reported a year ago. The Zacks Consensus Estimate for Health Catalyst has increas ...

Shares of Health Catalyst (HCAT) have gained 11.6% over the past four weeks to close the last trading session at $6.73, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.79 indicates a potential upside of 75.2%. The average comprises 14 short-term price targets ranging from a low of $8 to a high of $16, with a standard deviation of $2.72. While the lowest estimate indicates an ...

SALT LAKE CITY, May 21, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of Health Catalyst Ignite®, a next-generation healthcare data and analytics ecosystem that combines best-in-class technologies, healthcare-specific data models, self-service tools, and industry expertise in one modern environment. Today's health systems face significant challenges in navig ...

Health Catalyst (HCAT) reported $74.72 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 1.2%. EPS of $0.05 for the same period compares to $0.05 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $74.81 million, representing a surprise of -0.11%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being $0.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...

Health Catalyst (HCAT) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this provider of data analytics for the health care industry would post a loss of $0.01 per share when it actually produced earnings of $0.02, delivering a surprise of 30 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38993 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter ...

[Q1 2024 Financial and Operational Highlights](index=1&type=section&id=Q1%202024%20Financial%20and%20Operational%20Highlights) Health Catalyst reported strong Q1 2024 financial results, exceeding guidance for revenue and Adjusted EBITDA, and reaffirmed full-year 2024 outlook - CEO Dan Burton highlighted the strong financial performance in Q1 2024, beating guidance for both **revenue** and **Adjusted EBITDA**, and reaffirmed the full-year 2024 outlook[3](index=3&type=chunk) Q1 2024 Key Financial Metrics (vs. Q1 2023) | Metric | Q1 2024 | Q1 2023 | YoY Change | | :--- | :--- | :--- | :--- | | **GAAP Measures** | | | | | Total Revenue | $74.7M | $73.9M | 1% | | Gross Profit | $29.3M | $28.2M | 4% | | Gross Margin | 39% | 38% | +1 ppt | | Net Loss | $(20.6)M | $(33.2)M | 38% improvement | | **Non-GAAP Measures** | | | | | Adjusted Gross Profit | $38.3M | $38.4M | 0% | | Adjusted Gross Margin | 51% | 52% | -1 ppt | | Adjusted EBITDA | $3.4M | $4.2M | (19)% | [Financial Outlook](index=2&type=section&id=Financial%20Outlook) The company projects Q2 2024 revenue between $73.5M and $76.5M, with full-year revenue expected to range from $304.0M to $312.0M Q2 2024 Financial Guidance | Metric | Guidance Range | | :--- | :--- | | Total Revenue | $73.5M - $76.5M | | Adjusted EBITDA | $5.0M - $7.0M | Full Year 2024 Financial Guidance | Metric | Guidance Range | | :--- | :--- | | Total Revenue | $304.0M - $312.0M | | Adjusted EBITDA | $24.0M - $26.0M | [Condensed Consolidated Financial Statements](index=4&type=section&id=Condensed%20Consolidated%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for Q1 2024, including Balance Sheets, Statements of Operations, and Cash Flows [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets were $695.1 million as of March 31, 2024, with cash and cash equivalents significantly increasing to $201.4 million Balance Sheet Highlights (in thousands) | Account | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $201,370 | $106,276 | | Short-term investments | $126,415 | $211,452 | | Total current assets | $397,136 | $393,397 | | Total assets | $695,112 | $701,814 | | Total current liabilities | $92,208 | $89,034 | | Total liabilities | $337,902 | $334,895 | | Total stockholders' equity | $357,210 | $366,919 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2024 total revenue increased 1% to $74.7 million, with net loss significantly reduced to $20.6 million due to lower operating expenses Q1 2024 Statement of Operations (in thousands, except per share data) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Technology Revenue | $46,966 | $47,186 | | Professional Services Revenue | $27,757 | $26,682 | | **Total Revenue** | **$74,723** | **$73,868** | | Loss from operations | $(22,812) | $(34,914) | | **Net loss** | **$(20,587)** | **$(33,190)** | | Net loss per share | $(0.35) | $(0.60) | - General and administrative expenses decreased significantly from **$23.8 million** in Q1 2023 to **$14.6 million** in Q1 2024, largely due to **$11.7 million** in litigation costs in Q1 2023 that did not recur[15](index=15&type=chunk)[18](index=18&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The company generated $10.3 million in cash from operating activities in Q1 2024, with cash and cash equivalents increasing to $201.4 million Cash Flow Summary (in thousands) | Cash Flow Activity | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $10,266 | $(5,580) | | Net cash provided by investing activities | $83,984 | $22,649 | | Net cash provided by financing activities | $863 | $93 | | **Net increase in cash and cash equivalents** | **$95,094** | **$17,167** | | **Cash and cash equivalents at end of period** | **$201,370** | **$133,479** | [Reconciliation of GAAP to Non-GAAP Financial Measures](index=8&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Financial%20Measures) This section reconciles GAAP to non-GAAP financial measures, including Adjusted Gross Profit, Adjusted EBITDA, and Adjusted Net Income, for performance evaluation - The company uses non-GAAP measures to supplement its GAAP financial information, believing they provide consistency and comparability with past performance by excluding certain non-cash and non-recurring expenses[22](index=22&type=chunk)[23](index=23&type=chunk) [Adjusted Gross Profit and Adjusted Gross Margin](index=8&type=section&id=Adjusted%20Gross%20Profit%20and%20Adjusted%20Gross%20Margin) Q1 2024 Adjusted Gross Profit was $38.3 million, with Adjusted Gross Margin slightly decreasing to 51% year-over-year Reconciliation of Gross Profit to Adjusted Gross Profit (in thousands) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Gross profit (GAAP) | $29,321 | $28,158 | | Add: Depreciation and amortization | $6,885 | $7,406 | | Add: Stock-based compensation | $1,697 | $2,190 | | Add: Acquisition-related costs, net | $156 | $172 | | Add: Restructuring costs | $260 | $446 | | **Adjusted Gross Profit (Non-GAAP)** | **$38,319** | **$38,372** | [Adjusted EBITDA](index=10&type=section&id=Adjusted%20EBITDA) Adjusted EBITDA for Q1 2024 was $3.4 million, a decrease from $4.2 million in Q1 2023, after adjusting for various non-recurring costs Reconciliation of Net Loss to Adjusted EBITDA (in thousands) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net loss (GAAP) | $(20,587) | $(33,190) | | Add: Interest and other (income) expense, net | $(2,338) | $(1,793) | | Add: Income tax provision | $113 | $69 | | Add: Depreciation and amortization | $10,525 | $10,994 | | Add: Stock-based compensation | $10,838 | $13,884 | | Add: Acquisition-related costs, net | $813 | $481 | | Add: Litigation costs | — | $11,664 | | Add: Restructuring costs | $1,813 | $2,055 | | Add: Non-recurring lease-related charges | $2,200 | — | | **Adjusted EBITDA (Non-GAAP)** | **$3,377** | **$4,164** | [Adjusted Net Income and Adjusted Net Income Per Share](index=11&type=section&id=Adjusted%20Net%20Income%20and%20Adjusted%20Net%20Income%20Per%20Share) Q1 2024 Adjusted Net Income was $2.7 million, with Adjusted Net Income per diluted share remaining constant at $0.05 year-over-year Reconciliation of Net Loss to Adjusted Net Income (in thousands) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net loss (GAAP) | $(20,587) | $(33,190) | | Add: Stock-based compensation | $10,838 | $13,884 | | Add: Amortization of acquired intangibles | $7,251 | $7,780 | | Add: Restructuring costs | $1,813 | $2,055 | | Add: Acquisition-related costs, net | $813 | $481 | | Add: Litigation costs | — | $11,664 | | Add: Non-recurring lease-related charges | $2,200 | — | | Add: Non-cash interest expense | $379 | $377 | | **Adjusted Net Income (Non-GAAP)** | **$2,707** | **$3,051** | Adjusted Net Income Per Share | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Adjusted Net Income per share, basic | $0.05 | $0.05 | | Adjusted Net Income per share, diluted | $0.05 | $0.05 |